FindTrial
Sign In

Belimumab 1 mg/kg

DRUG7 trials

Sponsors

Human Genome Sciences Inc., Human Genome Sciences Inc., a GSK Company, GlaxoSmithKline

Conditions

Arthritis, RheumatoidLupus Erythematosus, DiscoidLupus Erythematosus, SystemicSystemic Lupus Erythematosus

Phase 2

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
CompletedNCT00071487
Human Genome Sciences Inc.Lupus Erythematosus, Systemic
Start: 2003-10-31End: 2006-06-30Updated: 2013-08-07
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
CompletedNCT00071812
Human Genome Sciences Inc.Arthritis, Rheumatoid
Start: 2003-12-31End: 2005-12-31Updated: 2013-08-14

Phase 3

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
CompletedNCT00410384
Human Genome Sciences Inc.Systemic Lupus Erythematosus
Start: 2006-12-31End: 2010-03-31Updated: 2017-02-01
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
CompletedNCT00424476
Human Genome Sciences Inc.Systemic Lupus Erythematosus
Start: 2007-05-31End: 2010-03-31Updated: 2016-12-12
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
CompletedNCT00724867
Human Genome Sciences Inc., a GSK CompanySystemic Lupus Erythematosus
Start: 2008-08-31End: 2015-03-31Updated: 2016-03-28

Unknown Phase

A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
CompletedNCT01858792
Human Genome Sciences Inc., a GSK CompanyLupus Erythematosus, Discoid
Start: 2011-05-31End: 2011-06-30Updated: 2013-05-21
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
CompletedNCT01914770
GlaxoSmithKlineSystemic Lupus Erythematosus
Start: 2009-07-31End: 2010-11-30Updated: 2013-09-16

Related Papers

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.
2026-07-03
Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.
2026-05-21
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a <i>post-hoc</i> summary of five phase 3 trials
Reumatismo2025-11-26
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Lupus2025-05-052 citations
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab.
2025-02-015 citations
Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms
Rheumatology Advances in Practice2025-01-011 citations
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
2024-09-017 citations
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
2024-08-2615 citations
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
Lupus Science & Medicine2024-05-012 citations
Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better <scp>Health‐Related</scp> Quality of Life
Arthritis Care & Research2024-01-233 citations
Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review
Current Therapeutic Research2024-01-013 citations
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
2023-07-01
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
2023-07-01
LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
2023-07-01
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials
Lara D. Veeken2023-05-2537 citations
Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
Lara D. Veeken2023-03-215 citations
EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
Frontiers in Medicine2022-12-2012 citations
PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus
2022-09-27
PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
2022-09-27
PO.7.149 Associations between abnormal bmi and patient-reported health-related quality of life before and after therapeutic intervention in patients with systemic lupus erythematosus
2022-09-27

29 more papers not shown